ShareValue scores for WWB: Valuation 42, Quality 50, Growth 50, Health 39.
WWBNASDAQ
Windward Bio Group AG Common Shares
$24.01
(+6.05%)
Updated
WWBNASDAQ
Windward Bio Group AG Common Shares
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
vs US-listed Healthcare stocks without a market-cap tier
Company Details
Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease. The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.
Score Analysis
AI Investment Thesis
Windward Bio Group AG Common Shares is fairly valued: its P/B of 6.20 is higher than 79% of US-listed healthcare peers, while P/E, EV/EBITDA and PEG are not available.
With no earnings, the decisive fundamental is the $225 million raised, funding a cash runway the company estimates covers up to $227.5 million of planned spending.
The key event was its November 13, 2026 Nasdaq debut, closing at $28.50, up 68% from the $17 IPO price for a roughly $1.69 billion valuation.